Virus Disease
13
0
1
7
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
1 terminated out of 13 trials
87.5%
+1.0% vs benchmark
15%
2 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
Viral Infections of the Central Nervous System: Diagnosis and Clinical Outcome
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
Prevalence of Myocardial Scars on CMR After COVID-19 Infection
Spread and Course of COVID-19 Infections
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration
A Rapid Test for Acute Respiratory Illness
Centralized Reminder Recall - Flu RCT2
The Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Health Neonates
Collection of Liver Tissue for Virologic Studies